tiprankstipranks
Advertisement
Advertisement

TSE:GILD Stock Latest News

Gilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir
The FlyGilead announces U.S. FDA accepted NDA submission for bictegravir, lenacapavir
7d ago
GILD
Gilead completes acquisition of Arcellx for $115 per share in cash
PremiumThe Fly
Gilead completes acquisition of Arcellx for $115 per share in cash
9d ago
ACLX
GILD
Gilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds
PremiumRatings
Gilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds
14d ago
GILD
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
PremiumThe Fly
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
16d ago
GILD
RCUS
Arcus Biosciences price target lowered to $47 from $49 at Leerink
PremiumThe Fly
Arcus Biosciences price target lowered to $47 from $49 at Leerink
16d ago
GILD
RCUS
Gilead receives all required regulatory approvals for Arcellx acquisition
PremiumThe FlyGilead receives all required regulatory approvals for Arcellx acquisition
20d ago
ACLX
GILD
Trump names Erica Schwartz CDC Director
Premium
The Fly
Trump names Erica Schwartz CDC Director
20d ago
AZN
BMY
Private Markets: Slate Auto, Plata land major rounds
Premium
The Fly
Private Markets: Slate Auto, Plata land major rounds
20d ago
ZS
ABM
Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
PremiumRatings
Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
22d ago
GILD
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
PremiumThe Fly
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
22d ago
GILD
Gilead put volume heavy and directionally bearish
PremiumThe Fly
Gilead put volume heavy and directionally bearish
23d ago
GILD
Gilead price target raised to $165 from $156 at Citi
PremiumThe Fly
Gilead price target raised to $165 from $156 at Citi
24d ago
GILD
Gilead price target raised to $175 from $171 at Morgan Stanley
PremiumThe FlyGilead price target raised to $175 from $171 at Morgan Stanley
27d ago
GILD
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
Premium
The Fly
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
27d ago
GILD
MGNX
Tempus AI announce strategic collaboration with Gilead
Premium
The Fly
Tempus AI announce strategic collaboration with Gilead
27d ago
TEM
GILD
Kymera Therapeutics announces Gilead option exercise to license KT-200
PremiumThe Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
28d ago
GILD
KYMR
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
29d ago
GILD
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
29d ago
GILD
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
PremiumRatings
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
29d ago
GILD
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
PremiumRatingsGilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
29d ago
GILD
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Premium
Ratings
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
29d ago
GILD
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
Premium
The Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
29d ago
GILD
IMNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >